Understand the importance of targeted assays in personalised medicine and how early decisions shape clinical outcomes.

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

Jeff Borgia, Ph.D. is the Director of the Rush Cancer Center Biorepository, where he oversees the collection and annotation of patient specimens in support of ongoing translational research projects ...

Optimizing PCR assays for assay development (AD) workflows typically involves a range of interdependent factors. These include thermocycling conditions, enzyme levels, buffer chemistry, and ...

Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

A good bioassay, like a good marriage, joins two partners in a bond and is mutually beneficial. In the case of bioassays, optimal design and development and accurate statistical analysis comprise a ...

Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...

Discover advancements in assay development and cell-based screening models with insights on AI, high-throughput screening, and toxicity detection from ELRIG Drug Discovery posters in this eBook.

In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper understanding of the development process, enabling you to streamline the ...

As AI accelerates target discovery and pushes more candidates toward the bench, assay development and transfer have become critical bottlenecks. Teams relying on one-factor-at-a-time (OFAT) workflows ...